This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Karihtala, P. Articles by Soini, Y. Search for Related Content PubMed PubMed Citation Articles by Karihtala, P. Articles by Soini, Y.

Peroxiredoxins in Breast Carcinoma¹

Department of Pathology, University of Oulu and Oulu University Hospital, 90014 Oulu, Finland [P. K., A. M., Y. S.]; The Center for Cell Signaling Research and Division of Molecular Life Sciences, Ewha Womans University, Seoul 120-750, Korea [S. W. K.]; and Department of Medicine, Division of Pulmonary Medicine, University of Helsinki and Helsinki University Hospital, 00014 Helsinki and Department of Internal Medicine, University of Oulu and Oulu University Hospital, 90014 Oulu, Finland [V. L. K.]

Purpose: Peroxiredoxins (Prxs) are a novel group of peroxidases containing high antioxidant efficiency and some of them having also effects on cell differentiation and apoptosis. The mammalian Prx family has six distinct members located in various subcellular locations, including peroxisomes and mitochondria, places where oxidative stress is most evident.

Experimental Design: We examined immunohistochemically a large set of samples from patients with breast carcinoma and investigated associations with parameters such as tumor-node-metastasis classification, hormone receptor status, and patient survival. Three biopsies of healthy breast tissue were used as controls.

Results: Expression of peroxiredoxins I, III, IV, and V was found in 80% of cases, whereas the expression of Prx II and VI was less frequent. Increased expression of Prx III was found to associate with the presence of progesterone (P = 0.02) and estrogen (P = 0.03) receptors, and Prxs IV (P = 0.009) and VI (P = 0.04) were overexpressed in progesterone receptor positive cases. Prx V was the only isoform that associated with items of tumor-node-metastasis classification, it was connected to a larger tumor size (P = 0.05) and positive lymph node status (P = 0.04). Prx V positivity was also connected with shorter survival (P = 0.04), whereas Prxs III (P = 0.002) and IV (P = 0.02) were related to better prognosis, probably resulting from their connection with a positive hormone receptor status.

Conclusions: In conclusion, we found that expression of peroxiredoxins, especially III, IV and V, is increased in breast malignancy, suggesting the induction of Prxs as response to increased production of reactive oxygen species in carcinomatous tissue.

This article has been cited by other articles:

				R. B. Parmigiani, W. S. Xu, G. Venta-Perez, H. Erdjument-Bromage, M. Yaneva, P. Tempst, and P. A. Marks HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation PNAS, July 15, 2008; 105(28): 9633 - 9638. [Abstract] [Full Text] [PDF]

				J.-H. Kim, P. N. Bogner, S.-H. Baek, N. Ramnath, P. Liang, H.-R. Kim, C. Andrews, and Y.-M. Park Up-Regulation of Peroxiredoxin 1 in Lung Cancer and Its Implication as a Prognostic and Therapeutic Target Clin. Cancer Res., April 15, 2008; 14(8): 2326 - 2333. [Abstract] [Full Text] [PDF]

				P. Karihtala, Y. Soini, P. Auvinen, R. Tammi, M. Tammi, and V.-M. Kosma Hyaluronan in Breast Cancer: Correlations With Nitric Oxide Synthases and Tyrosine Nitrosylation J. Histochem. Cytochem., December 1, 2007; 55(12): 1191 - 1198. [Abstract] [Full Text] [PDF]

				W. Lee, K.-S. Choi, J. Riddell, C. Ip, D. Ghosh, J.-H. Park, and Y.-M. Park Human Peroxiredoxin 1 and 2 Are Not Duplicate Proteins: THE UNIQUE PRESENCE OF CYS83 IN Prx1 UNDERSCORES THE STRUCTURAL AND FUNCTIONAL DIFFERENCES BETWEEN Prx1 AND Prx2 J. Biol. Chem., July 27, 2007; 282(30): 22011 - 22022. [Abstract] [Full Text] [PDF]

				Y. Fujita, T. Nakanishi, M. Hiramatsu, H. Mabuchi, Y. Miyamoto, A. Miyamoto, A. Shimizu, and N. Tanigawa Proteomics-Based Approach Identifying Autoantibody against Peroxiredoxin VI as a Novel Serum Marker in Esophageal Squamous Cell Carcinoma. Clin. Cancer Res., November 1, 2006; 12(21): 6415 - 6420. [Abstract] [Full Text] [PDF]

				L. True, I. Coleman, S. Hawley, C.-Y. Huang, D. Gifford, R. Coleman, T. M. Beer, E. Gelmann, M. Datta, E. Mostaghel, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma PNAS, July 18, 2006; 103(29): 10991 - 10996. [Abstract] [Full Text] [PDF]

				S. T. Lehtonen, P. M. H. Markkanen, M. Peltoniemi, S. W. Kang, and V. L. Kinnula Variable overoxidation of peroxiredoxins in human lung cells in severe oxidative stress Am J Physiol Lung Cell Mol Physiol, May 1, 2005; 288(5): L997 - L1001. [Abstract] [Full Text] [PDF]